HUMACYTE INC (HUMA)
US44486Q1031 - Common Stock
We assign a fundamental rating of 1 out of 10 to HUMA. HUMA was compared to 565 industry peers in the Biotechnology industry. Both the profitability and financial health of HUMA have multiple concerns. HUMA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
HUMA had negative earnings in the past year.
In the past year HUMA has reported a negative cash flow from operations.
In the past 5 years HUMA always reported negative net income.
In the past 5 years HUMA always reported negative operating cash flow.
1.2 Ratios
HUMA has a Return On Assets of -133.20%. This is amonst the worse of the industry: HUMA underperforms 83.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -133.2% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-33.83%
ROA(5y)-42.89%
ROE(3y)-283.23%
ROE(5y)-201.68%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for HUMA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
HUMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
HUMA has more shares outstanding than it did 1 year ago.
HUMA has a better debt/assets ratio than last year.
2.2 Solvency
HUMA has an Altman-Z score of -9.49. This is a bad value and indicates that HUMA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.49, HUMA is doing worse than 73.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.49 |
ROIC/WACCN/A
WACC10.3%
2.3 Liquidity
A Current Ratio of 1.10 indicates that HUMA should not have too much problems paying its short term obligations.
HUMA has a worse Current ratio (1.10) than 86.63% of its industry peers.
A Quick Ratio of 1.10 indicates that HUMA should not have too much problems paying its short term obligations.
HUMA has a worse Quick ratio (1.10) than 84.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.1 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
HUMA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -54.02%.
The Revenue for HUMA has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-54.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, HUMA will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.78% on average per year.
The Revenue is expected to grow by 464.78% on average over the next years. This is a very strong growth
EPS Next Y-16.16%
EPS Next 2Y9.39%
EPS Next 3Y22.42%
EPS Next 5Y16.78%
Revenue Next Year450.04%
Revenue Next 2Y1640.21%
Revenue Next 3Y1209.08%
Revenue Next 5Y464.78%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
HUMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HUMA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as HUMA's earnings are expected to grow with 22.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.39%
EPS Next 3Y22.42%
5. Dividend
5.1 Amount
HUMA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HUMACYTE INC
NASDAQ:HUMA (11/22/2024, 8:00:02 PM)
After market: 4.4 -0.09 (-2%)4.49
+0.11 (+2.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap561.38M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -133.2% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.1 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-54.02%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-16.16%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y